Stock Price Quote

THYROCARE TECHNOLOGIES LTD.

NSE : THYROCAREBSE : 539871ISIN CODE : INE594H01019Industry : Hospital & Healthcare ServicesHouse : MNC
BSE564.90-2.7 (-0.48 %)
PREV CLOSE ( ) 567.60
OPEN PRICE ( ) 566.00
BID PRICE (QTY) 565.10 (15)
OFFER PRICE (QTY) 566.05 (82)
VOLUME 983
TODAY'S LOW / HIGH ( )564.00 568.20
52 WK LOW / HIGH ( )342.55 662
NSE565.15-1.7 (-0.3 %)
PREV CLOSE( ) 566.85
OPEN PRICE ( ) 568.90
BID PRICE (QTY) 565.15 (1)
OFFER PRICE (QTY) 565.65 (20)
VOLUME 13363
TODAY'S LOW / HIGH( ) 563.25 569.55
52 WK LOW / HIGH ( )342.55 662
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-01 2000
Management Info
Rahul Guha - Chairman Rahul Guha - Managing Director
Registered Office

Address D - 37/1, T T C Industrial Area,M I D C,Turbhe,
Navi Mumbai,
Maharashtra-400703

Phone 022 3090 0000 / 2762 2762 / 8422945537

Email enquiry@thyrocare.com / compliance@thyrocare.com

Website www.thyrocare.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

18Aug Thyrocare Technologies informs about S
Thyrocare Technologies has informed that it enclosed disclosure under Re..
18Aug Thyrocare Technologies informs about d
Thyrocare Technologies has informed that the Exchange has received the d..
17Aug Thyrocare Technologies informs about
Thyrocare Technologies has informed that the exchange has received Discl..
14Aug Thyrocare Technologies’ promoter sells
Thyrocare Technologies’ promoter -- Docon Technologies has sold its 9.90..
13Aug Thyrocare Technologies informs about d
Thyrocare Technologies has informed that it attached disclosure received..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit501.71488.1
Gross Profit 666.3 2104
Operating Profit 791.22697.2
Net Sales 2256.67742.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr Agarwals Eye Hosp (BSE)
peergroup  5300.00 (1.30%)
M.Cap ( in Cr)2528.61
Narayana Hrudayalay. (BSE)
peergroup  1908.30 (1.03%)
M.Cap ( in Cr)38599.67
Apollo Hospital Ent. (BSE)
peergroup  8979.25 (0.21%)
M.Cap ( in Cr)128831.05
RainbowChildrenS Med (BSE)
peergroup  1467.30 (1.15%)
M.Cap ( in Cr)14733.76
Manipal Health Enter (BSE)
peergroup  742.95 (1.78%)
M.Cap ( in Cr)96015.96

Shareholding Pattern

PROMOTERS 60.92%
MUTUAL FUNDS/UTI 19.86%
NON-INSTITUTION 12.72%
FI/BANKS/INSURANCE 0.12%
GOVERNMENT 0%
FII 0%

About Thyrocare Technologies Ltd.

Thyrocare Technologies Ltd. was incorporated in the year 2000. Its today's share price is 564.9. Its current market capitalisation stands at Rs 9034.22 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7742.7 Cr and Total Income of Rs.8049.7 Cr. The company's management includes Gaurav Verma, Uday Patel Kadam, Anandh Sundar, Nishant A Shah, Harshil Jiten Vora, Prapti Ishwar Gilada, Indumati Gopinathan, Alok Kumar Jagnani, Rahul Guha, Rahul Guha, Brijesh Kumar.

It is listed on the BSE with a BSE Code of 539871 , NSE with an NSE Symbol of THYROCARE and ISIN of INE594H01019. It's Registered office is at D - 37/1, T T C Industrial Area,M I D C,TurbheNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co, BSR & Co LLP, MSKA & Associates, MSKA & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.